Merck, Sharp & Dohme Inc. (MSD) (NYSE: MRK) announced the initiation of ENHANCE‑3 (NCT07874815), a Phase 3 randomized clinical trial evaluating OHTUVAYRE (ensifentrine) for the prevention of chronic obstructive pulmonary disease (COPD) exacerbations in adult patients receiving standard of care (SOC) with a history of exacerbations.
Trial Initiation Snapshot
| Item | Detail |
|---|---|
| Sponsor | Merck, Sharp & Dohme Inc. (MSD) |
| Trial | ENHANCE‑3 (NCT07874815), Phase 3 randomized |
| Drug | OHTUVAYRE (ensifentrine), inhaled |
| Objective | Prevention of COPD exacerbations in adults on SOC with exacerbation history |
| Planned Enrollment | ~2,136 patients across 28 countries |
| Primary Endpoint | Annualized rate of adjudicated moderate or severe COPD exacerbations |
| Announcement Date | 4 Nov 2026 |
Drug Profile & Mechanism of Action
- Molecule: Ensifentrine, an inhaled therapy administered for maintenance treatment of COPD in adults.
- Target: First‑in‑class selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4).
- Innovation: The first and only inhaled COPD maintenance therapy to combine bronchodilation (via PDE3 inhibition) and non‑corticosteroid anti‑inflammatory effects (via PDE4 inhibition) in one molecule – offering a steroid‑sparing mechanism for patients with chronic airway inflammation.
- Regulatory Status: Approved by the U.S. Food and Drug Administration (FDA) in June 2024 for the maintenance treatment of COPD in adult patients, based on the ENHANCE‑1 and ENHANCE‑2 pivotal studies.
Clinical Evidence – ENHANCE‑3 Phase 3 Trial Design
| Endpoint Category | Measure |
|---|---|
| Primary | Annualized rate of adjudicated moderate or severe COPD exacerbations |
| Secondary | Lung function |
| Secondary | Health‑related quality of life |
| Secondary | Severe exacerbations |
| Secondary | Safety |
ENHANCE‑3 plans to enroll approximately 2,136 patients with a history of at least one moderate or severe COPD exacerbation in the previous year while receiving standard of care, across 28 countries worldwide – a large, globally diversified population designed to test whether ensifentrine added to SOC can reduce the exacerbation burden that drives COPD morbidity, hospitalization, and mortality.
Market Impact & Outlook
- Indication Expansion: OHTUVAYRE is currently approved for maintenance treatment; ENHANCE‑3 targets exacerbation prevention – a distinct, higher‑value label claim in a patient subgroup (frequent exacerbators) with the greatest unmet need.
- Differentiated Positioning: As the only inhaled single‑molecule therapy combining bronchodilation with non‑corticosteroid anti‑inflammatory action, ensifentrine competes on mechanism against inhaled corticosteroid‑containing regimens and other maintenance therapies.
- Competitive Landscape: Exacerbation‑rate reduction is the marquee endpoint in COPD drug development; positive ENHANCE‑3 data would strengthen OHTUVAYRE’s commercial trajectory in a multibillion‑dollar respiratory market.
- Timeline: Data timing for ENHANCE‑3 was not disclosed in the announcement.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Merck’s ENHANCE‑3 clinical trial, including enrollment, endpoint outcomes, and the potential therapeutic profile of OHTUVAYRE (ensifentrine). Actual results may differ due to risks including trial execution and enrollment challenges, clinical outcomes, regulatory decisions, and competitive dynamics in the COPD market.-Fineline Info & Tech
